Gilead Buying CGI Pharma for $120 Million
Gilead Sciences Inc. (Nasdaq: GILD) has agreed to acquire CGI Pharmaceuticals Inc., a Branford, Conn.-based drug developer focused on small molecule chemistry and kinase biology. The deal is valued at $120 million, the majority of which is an up-front cash payment.
25 June 2010•3 mins read
